AWARDS
COMMUNITY PHARMACY SERVICE INITIATIVE
supported by Your Partner of Choice
CHARLES MICHIE, CHARLES MICHIES PHARMACY, ABERDEEN
Due to the success of the pharmacy’s fl u vaccination service during a pilot, Charles agreed to continue the service in the following years, provided, of course, that the Patient Group Directions could extend to include private patients. Since then, the pharmacy has provided a highly successful and nationally-renowned clinic service where an appointment or walk-in fl u vaccination service is available to the city of Aberdeen. The pharmacy also runs a very successful Travel Health Clinic, which was launched in response to the fact that many travellers were being either turned away from their GP Practices’ travel clinics, or were struggling to fi nd a suitable appointment time, especially if it was required within a six-week window.
RICHARD GRAEME, CALLENDAR PHARMACY, FALKIRK
Forth Valley launched its Pharmacy First initiative earlier this year. What sets Callendar Pharmacy apart from the other pharmacies in the Forth Valley board area is that contractor, Richard Graeme, has engaged fully with the local GPS in ‘Create Days’, where he speaks to the GPs in order to promote the new services. Richard also engages with the receptionists as it is they, who come face to face with patients on a daily basis. Richard and his team are highly active in promoting all of their services to their local community. He regularly runs radio campaigns for the fl u vaccinations and the smoking cessation service on Central FM radio, where he advertises initiatives such as, if a patient does not receive their prescription within ten minutes, it will be delivered to their home for free.
LAUREN CLARKE, DAVIDSONS CHEMISTS, FORFAR, ANGUS
In December last year, Lauren and her team were asked to take part in development work for the HCV service. The main objective was to check the infection status of all patients eligible for the study and then obtain a cure for infected patients. Lauren carried out a dry blood spot testing for each of the pharmacy’s opioid substitution therapy patients and, to date, every patient, who has commenced treatment in the pharmacy has received their twelve-week, post-treatment viral response.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
